Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery

Lawsuit Overview - A class action securities lawsuit has been filed against Regeneron Pharmaceuticals Inc (NASDAQ: REGN) on behalf of investors who suffered losses between November 2 2023 and October 30 2024 due to alleged securities fraud [3] - The lawsuit seeks to recover losses for investors adversely affected by the alleged misconduct during the specified period [3] Allegations - Regeneron allegedly paid credit card fees to distributors on the condition that they did not charge Eylea customers more for using credit cards [4] - These payments subsidized the prices customers paid when using credit cards to purchase Eylea resulting in price concessions that lowered Eylea's selling price [4] - The price concessions provided a competitive advantage as retina practices were sensitive to higher prices when purchasing anti-VEGF medications with credit cards [4] - Regeneron allegedly boosted reported Eylea sales misleadingly by failing to report the payment of credit card fees as price concessions [4] - The company overstated the Average Selling Price (ASP) reported to federal agencies violating the False Claims Act [4] - Defendants' positive statements about the company's business operations and prospects were allegedly materially misleading and/or lacked a reasonable basis [4] Legal Representation - Levi & Korsinsky LLP a law firm with over 20 years of experience in securities litigation is representing the aggrieved shareholders [5] - The firm has secured hundreds of millions of dollars for shareholders and has a track record of winning high-stakes cases [5] - Levi & Korsinsky has been ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [5] Investor Participation - Investors who suffered losses in Regeneron during the relevant period have until March 10 2025 to request the Court to appoint them as lead plaintiff [1] - Participation in the lawsuit does not require serving as a lead plaintiff and there is no cost or obligation for class members to participate [1]